Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Carboplatin/erlotinib/pemetrexed

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Hadfield MJ, et al. Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R. Journal of Oncology Pharmacy Practice 28: 717-721, No. 3, Apr 2022. Available from: URL: http://doi.org/10.1177/10781552211057867 Hadfield MJ, et al. Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R. Journal of Oncology Pharmacy Practice 28: 717-721, No. 3, Apr 2022. Available from: URL: http://​doi.​org/​10.​1177/​1078155221105786​7
Metadaten
Titel
Carboplatin/erlotinib/pemetrexed
Lack of efficacy: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15385-x

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Apalutamide

Case report

Antineoplastics

Case report

Tozinameran